Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesia

19 Apr 2019

Abstract excerpt

BACKGROUND: Levodopa-induced dyskinesias are an often debilitating side effect of levodopa therapy in Parkinson's disease. Although up to 90% of individuals with PD develop this side effect, uniformly effective and well-tolerated antidyskinetic treatment remains a significant unmet need. The pathognomonic loss of striatal dopamine in PD results in dysregulation and disinhibition of striatal CaV1.3 calcium...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiac electrophysiology and arrhythmias
Share to Neurological disorders and treatments
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31002755
DOI: 10.1002/mds.27695

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesiaPMID 31002755Read ↗

Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph diseaseSemantic proximity Read ↗

Dopamine D3 Receptor Plasticity in Parkinson’s Disease and L-DOPA-Induced DyskinesiaSemantic proximity Read ↗

Genetic suppression of the dopamine D3 receptor in striatal D1 cells reduces the development of L-DOPA-induced dyskinesiaSemantic proximity Read ↗

Knockdown of GAD67 protein levels normalizes neuronal activity in a rat model of Parkinson's diseaseSemantic proximity Read ↗

Pharmacological targeting of dopamine D1 or D2 receptors evokes a rapid-onset parkinsonian motor phenotype in mice.Semantic proximity Read ↗

Dopamine Gene Therapy for Parkinson’s Disease in a Nonhuman Primate Without Associated DyskinesiaSemantic proximity Read ↗

Gene therapy for Parkinson's diseaseSemantic proximity Read ↗

Effect of levodopa/carbidopa on the progression of Machado-Joseph disease /spinocerebellar ataxia type 3 (MJD/SCA3)Semantic proximity Read ↗

Mpdz expression in the caudolateral substantia nigra pars reticulata is crucially involved in alcohol withdrawal.Semantic proximity Read ↗

Decrease of a Current Mediated by Kv1.3 Channels Causes Striatal Cholinergic Interneuron Hyperexcitability in Experimental Parkinsonism.Semantic proximity Read ↗

Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice.Semantic proximity Read ↗

Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.